Wilate

DRUG8 trials

Sponsors

Octapharma AG, Octapharma, University of California, Davis, Emory University, University Hospital, Basel, Switzerland

Conditions

BleedingHemophilia AHemophilia A With InhibitorSevere Hemophilia AVon Willebrand DiseaseVon Willebrand Disease Von Willebrand DiseaseVon Willebrand Diseases

Phase 3

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

CompletedNCT02954575

OctapharmaSevere Hemophilia A

Start: 2016-12-31End: 2018-03-29Updated: 2021-01-19

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

CompletedNCT03376516

OctapharmaSevere Hemophilia A

Start: 2017-11-22End: 2018-11-03Updated: 2021-01-19

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

CompletedNCT04052698

OctapharmaVon Willebrand Diseases

Start: 2020-06-18End: 2022-04-23Updated: 2023-10-25

CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF WILATE DURING PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH VON WILLEBRAND DISEASE (VWD)

Active, not recruitingLBCTR2020063508

Octapharma AGVon Willebrand Disease Von Willebrand Disease

Start: 2020-06-01Target: 28Updated: 2026-02-02

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

CompletedNCT04953884

OctapharmaVon Willebrand Disease

Start: 2021-09-22End: 2024-12-16Updated: 2026-02-20

Phase 4

INdividualized ITI Based on Fviii(ATE) Protection by VWF

TerminatedNCT03204539

University of California, DavisHemophilia A, Hemophilia A With Inhibitor

Start: 2017-06-01End: 2019-07-19Updated: 2020-05-29

Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor

RecruitingNCT04555785

University Hospital, Basel, SwitzerlandBleeding

Start: 2022-04-01End: 2028-11-01Target: 120Updated: 2026-06-11

Unknown Phase

Treatment of Hemophilia A Patients With FVIII Inhibitors

RecruitingNCT04023019

Emory UniversityHemophilia A

Start: 2020-03-17End: 2029-06-30Target: 120Updated: 2025-09-05

Related Papers

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

European Journal Of Haematology2026-01-30

Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: First results from wil-33

Blood2025-11-03

Pharmacokinetic-pharmacodynamic modelling of von willebrand factor/factor VIII prophylaxis in von willebrand disease

Blood2025-11-03

Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective

Blood2025-11-03

Individualizing dosing frequency may improve the efficacy of prophylaxis in patients with von Willebrand disease-a WIL-31 subanalysis.

2025-10-10

Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease.

2025-05-021 citations

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups

Blood2024-11-05

Increased Prophylactic Dosing Frequency Effectively Improve Bleeding Rates in Von Willebrand Disease Patients Who Require Higher Hemostatic Coverage - a Sub-Analysis of Data from the Wil-31 Study

Blood2024-11-05

FVIII and VWF PK: Key Aspects in Safety and Efficiency of VWF Concentrates. Review and Reflection

Blood2024-11-05

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Blood2024-11-05

von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease

Blood Advances2024-01-1817 citations

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease

Blood2023-11-022 citations

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Blood2023-11-021 citations

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Blood2023-11-02

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Blood2023-11-02

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Blood2023-11-02

PB0841 Investigation of VWD in Women with Menorrhagia or Dysmenorrhea Associated with Bleeding

Research and Practice in Thrombosis and Haemostasis2023-10-01

Impact of Additional Administration of von Willebrand Factor Concentrates to Thrombocyte Transfusion in Perioperative Bleeding in Cardiac Surgery

Transfusion Medicine and Hemotherapy2023-07-111 citations

Enhancement of the haemostatic effect of platelets in the presence of high normal concentrations of von Willebrand factor for critically ill patients needing platelet transfusion—a protocol for the will-plate randomised controlled trial

Trials2023-01-201 citations

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Blood2022-11-15

2 more papers not shown